Research

Adherence

Current economic models often undervalue incretin therapies by excluding downstream benefits (e.g., reduced MACE, sleep apnea, osteoarthritis), leading to high ICERs that may exceed willingness-to-pay thresholds without price reductions.

For payers, these drugs are expensive. However, if you account for long-term health savings (fewer heart attacks, surgeries), they can be cost-effective, especially if the price is lowered or targeted at high-risk patients.

ModerateQualifiesMEDIUM confidence
The CDA’s 2022 economic reanalysis assumed approximately 3 years of treatment use... The analysis suggested that a price reduction of 71% would be required for semaglutide to be cost-effective... Traditional HTA designs are built around single-disease endpoints and are therefore likely to undervalue these therapies.
Luke Awadalla et al. · Canadian Journal of Physiology and Pharmacology · 2026

Why this rating

Based on economic modeling studies and HTA reports, which vary in assumptions.

Source

Cost-effectiveness of incretin therapies: a Canadian lens on diabetes, obesity, and emerging indications

Luke Awadalla et al. · Canadian Journal of Physiology and Pharmacology · 2026

DOI 10.1139/cjpp-2025-0248

narrative_review
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →